Aug 11, 2020
Eisai Announces Topline Results from Study 211 Supporting 24 mg as the Appropriate Starting Dose for LENVIMA® (lenvatinib) in Patients with Differentiated Thyroid Cancer
Mar 19, 2020
Positive Results from Registrational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the Journal of Clinical Oncology
Feb 15, 2020
Eisai Announces Latest Data for LENVIMA® (lenvatinib) in Combination with Everolimus for Advanced Non-Clear Cell Renal Cell Carcinoma
Feb 10, 2020
Eisai to Present Latest on LENVIMA® (lenvatinib) at the 2020 Genitourinary Cancers Symposium
Jan 21, 2020
Eisai to Present Latest Data on LENVIMA® (lenvatinib) at the 2020 Gastrointestinal Cancers Symposium
Sep 24, 2019
Eisai Announces Data Presentations on KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin) at ESMO 2019
May 16, 2019
Eisai Announces Data Presentations on Oncology Pipeline, including LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Investigational Combination Therapy at ASCO 2019
Oct 09, 2018
Eisai to Present LENVIMA® (lenvatinib) and HALAVEN® (eribulin) Data in a Variety of Advanced Cancers at ESMO 2018 Congress
Oct 08, 2018
Hepatocellular Carcinoma- Rich Clinical Pipeline can Lead to an Increasing Market Size of USD 3.8 Billion by 2027 for G8 Countries
May 24, 2018
Eisai And Merck Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib in First-Line Unresectable Hepatocellular Carcinoma
May 17, 2018
Eisai Announces Data at ASCO 2018 Annual Meeting Showcasing LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy Under Strategic Oncology Collaboration with Merck
Feb 15, 2018
Positive Phase 3 Trial Results of Investigational Anticancer Agent Lenvatinib in Unresectable Hepatocellular Carcinoma (HCC) Published in The Lancet
Jan 19, 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Sep 10, 2017
Lenvatinib Delays Deterioration in Certain Domains of Quality of Life in Patients with Unresectable Hepatocellular Carcinoma as Compared to Sorafenib in Phase 3 REFLECT Study
Aug 31, 2017
Eisai to Present New Clinical Data in Variety of Advanced Cancers at the ESMO 2017 Congress
Aug 28, 2017
Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According to Results of Subanalysis of Phase 3 SELECT Trial
Jul 25, 2017
Eisai Submits Supplemental New Drug Application to FDA for Lenvatinib in First-Line Hepatocellular Carcinoma
Jun 04, 2017
Lenvatinib Demonstrates Positive Results vs Sorafenib Across All Endpoints in First-Line Phase 3 Non-inferiority Trial of Unresectable Hepatocellular Carcinoma (uHCC)
Jun 03, 2017
Further Study of Combination of Eisai's Lenvatinib and Merck's Pembrolizumab in Previously Treated Patients with Metastatic Endometrial Cancer Supported by Interim Analysis of Ongoing Phase 1b/2 Trial